Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eprosartan · 1 trial · 1 indication
Change from baseline of diastolic blood pressure (DBP), sitting
| Arm | Type | Description |
|---|---|---|
| Eprosartan | EXPERIMENTAL | Eprosartan + Placebo Eprosartan Mesylate |
| Eprosartan Mesylate | ACTIVE_COMPARATOR | Eprosartan Mesylate + Placebo Eprosartan |
| Name | Type | Description |
|---|---|---|
| Eprosartan | DRUG | Eprosartan 450 mg |
| Eprosartan Mesylate | DRUG | Eprosartan mesylate 600 mg |
| Placebo Eprosartan mesylate | DRUG | Placebo Eprosartan mesylate |
| Placebo Eprosartan | DRUG | Placebo Eprosartan |
Inclusion Criteria * Males or females with essential hypertension, blood pressure values between 140 mmHg and 179 mmHg systolic and between 90 mmHg and 109 mmHg diastolic * Given written informed consent prior to starting the study Exclusion Criteria * Women with childbearing potential, breast fe...
Eprosartan is used for the treatment of essential hypertension, a condition of chronically elevated blood pressure. It is a small molecule cardiovascular therapy being developed by Abbott Laboratories. The drug is currently in Phase 3 clinical development and is being studied as a treatment to lower blood pressure in patients with this condition.
Eprosartan is an angiotensin II receptor blocker, meaning it works by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict. By blocking this hormone, Eprosartan helps relax blood vessels, which lowers blood pressure. This mechanism is relevant to its use in treating essential hypertension.
Eprosartan is being developed by Abbott Laboratories, a company traded on the stock exchange under the ticker symbol ABT. The drug is currently in Phase 3 clinical trials for the treatment of essential hypertension, a cardiovascular condition.
Eprosartan is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied for the treatment of essential hypertension, and its Phase 3 trial has been completed.
Eprosartan has one completed Phase 3 clinical trial registered under the identifier NCT01631227. This trial, titled 'Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension,' enrolled 665 participants and was conducted in Germany, Russia, and the United Kingdom.
Eprosartan and Eprosartan Mesylate are related but distinct forms of the same drug. Eprosartan Mesylate is a salt form of Eprosartan, and the two are being compared in a clinical trial to evaluate their effects on blood pressure in patients with essential hypertension.